Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO Sells $1,382,400.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao sold 90,000 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $15.36, for a total value of $1,382,400.00. Following the transaction, the chief executive officer now directly owns 2,093,100 shares in the company, valued at approximately $32,150,016. This represents a 4.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Alignment Healthcare Price Performance

ALHC opened at $15.79 on Friday. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 1.82. Alignment Healthcare, Inc. has a 12 month low of $4.46 and a 12 month high of $16.25. The company has a fifty day simple moving average of $14.38 and a 200 day simple moving average of $12.43. The stock has a market cap of $3.03 billion, a P/E ratio of -20.51 and a beta of 1.49.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ALHC. JPMorgan Chase & Co. upped their price objective on Alignment Healthcare from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Thursday, March 6th. Piper Sandler upped their price objective on Alignment Healthcare from $14.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Bank of America upped their price objective on Alignment Healthcare from $15.50 to $18.50 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Barclays upped their price objective on Alignment Healthcare from $8.00 to $9.00 and gave the stock an “underweight” rating in a report on Friday, February 28th. Finally, Stifel Nicolaus upped their price objective on Alignment Healthcare from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Institutional Trading of Alignment Healthcare

A number of large investors have recently made changes to their positions in ALHC. R Squared Ltd bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $55,000. RiverPark Advisors LLC bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $106,000. Tower Research Capital LLC TRC increased its position in shares of Alignment Healthcare by 146.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company’s stock valued at $119,000 after buying an additional 6,286 shares in the last quarter. Ballentine Partners LLC bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $121,000. Finally, Aigen Investment Management LP bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $129,000. Institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.